PROMOTE · PRostate cancer OMics Oriented inTErvention
„Хоризонт Европа“ — Действия „Мария Склодовска-Кюри“
- Период
- 2024-09-01 → 2028-08-31
- Финансиране от ЕС
- 2 049 185 €
- Участници
- 15
- Схема
- HORIZON-TMA-MSCA-DN-ID
Линиите свързват координатора с партньорите.
Накратко на български
Нови инструменти, базирани на изкуствен интелект и биомаркери, помагат за по-точно разпознаване на видовете рак на простатата. Това е важно, за да се избегне излишното лечение на пациенти с бавно развиващ се рак и да се подобрят терапиите при напреднали случаи.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Цел на проекта
PROMOTE focuses on multidisciplinary education of doctoral candidates (DCs) in -omics and artificial intelligence (AI) mediated intervention to improve clinical management of Prostate Cancer (PCa). PCa is the second most common malignancy, affecting ~1.3 million men every year worldwide. Tragically, there is a treatment paradox, as ~45% of PCa patients experience slow-growing cancer and are unlikely to progress rapidly, while PCa is not curable at advanced stage. Evidently, clinical management of PCa is not optimal, as patients which do not require treatment are over-treated, while for those that immediate actions are required, efficient treatment are still needed. To fill the above gaps, PROMOTE was formed to educate DCs in emerging -omics and AI technologies and deliver:a) novel non-invasive tools (based on biomarker- and AI- models) to guide intervention, andb) more efficient treatment options for advanced PCa (particularly metastatic) driven by molecular characterisation of the disease phenotypes.PROMOTE brings together 13 leading centers from different disciplines, including 3 SMEs, 4 university hospitals with clinical laboratories and 2 research institutes and 4 universities, closely collaborating with solid scientific background, as demonstrated by multiple publications. PROMOTE research builds on:i) available biobanks and -omics datasets within PROMOTE consortium, including >3000 urinary proteomics, >1100 imaging datasets paired with biopsy and pathology data, >350 paired RNA and proteomics urinary profiles, >100 tissue proteomics and ~300 phospho, proteo-genomic and transcriptomics profiles from public repositories,ii) established software and analytical protocols on -omics data integration, AI feature extraction and integration, systems biology, pathway enrichment, drug repurposing and in vitro testing, andiii) infrastructure to support hosting and training of DCs.Moreover, PROMOTE training programme has strong innovation and industrial focus.
Оригинален текст от CORDIS (на английски).
Участници
- MOSAIQUES DIAGNOSTICS GMBH · HannoverКоординаторГермания
- DELTA 4 GMBH · WIENАвстрия
- ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON · ATHINAГърция
- FACULDADE DE CIENCIAS DA UNIVERSIDADE DE LISBOA · LisboaПортугалия
- FCIENCIAS.ID - ASSOCIACAO PARA A INVESTIGACAO E DESENVOLVIMENTO DE CIENCIAS · LisbonПортугалия
- IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON · AthinaГърция
- KRESK TECNOLOGIAS DE INFORMACAO LDA · LISBOAПортугалия
- MEDIZINISCHE UNIVERSITAT INNSBRUCK · InnsbruckАвстрия
- RHEINISCH-WESTFAELISCHE TECHNISCHE HOCHSCHULE AACHEN · AachenГермания
- SERVICIO ANDALUZ DE SALUD · SevillaИспания
- UNIDADE LOCAL DE SAUDE DE SAO JOSE EPE · LISBOAПортугалия
- UNIVERSITAET zu LUEBECK · LubeckГермания
- UNIVERSITAT WIEN · WienАвстрия
- UNIVERSITATSKLINIKUM SCHLESWIG-HOLSTEIN · LübeckГермания
- UNIWERSYTET WROCLAWSKI · WroclawПолша
Връзки
Данни: CORDIS, © Европейски съюз